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Available online xxxxPatients diagnosed with glioblastoma (GBM) continue to face a bleak prognosis. It is critical that new effective
therapeutic strategies are developed. GBM stem cells have molecular hallmarks of neural stem and progenitor
cells and it is possible to propagate both non-transformed normal neural stem cells and GBM stem cells, in de-
fined, feeder-free, adherent culture. These primary stem cell lines provide an experimental model that is ideally
suited to cell-based drug discovery or genetic screens in order to identify tumour-specific vulnerabilities. For
many solid tumours, including GBM, the genetic disruptions that drive tumour initiation and growth have now
been catalogued. CRISPR/Cas-based genome editing technologies have recently emerged, transforming our abil-
ity to functionally annotate the human genome. Genome editing opens prospects for engineering precise genetic
changes in normal and GBM-derived neural stem cells, which will provide more defined and reliable genetic
models, with critical matched pairs of isogenic cell lines. Generation of more complex alleles such as knock in
tags or fluorescent reporters is also now possible. These new cellular models can be deployed in cell-based phe-
notypic drug discovery (PDD). Herewe discuss the convergence of these advanced technologies (iPS cells, neural
stem cell culture, genome editing and high content phenotypic screening) and how they herald a new era in
human cellular genetics that should have a major impact in accelerating glioblastoma drug discovery.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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The prognosis for children and adults suffering from high grade gli-
oma is dismal. An improved understanding of disease biology is urgent-
ly needed. Gliomas are a heterogeneous group of tumours, but the
higher grade tumours – more commonly known as glioblastoma
(GBM) – are invariably driven by cells that display features of neural
stem and progenitor cells (Lathia et al., 2015). Many putative genetic
and epigenetic drivers of gliomahave nowbeen uncovered through sys-
tematic genome-wide molecular annotation, opening up a wealth of
newdirections for fundamental discovery and improvedmolecular clas-
sifications (Brennan et al., 2013; Sturm et al., 2012). This fundamental
knowledge will ultimately lead to new treatments and enhanced pa-
tient outcomes; however, in the shorter term there remains an urgent
unmet need to repurpose existing drugs for use in GBM as well as iden-
tify key molecular targets and develop new lead compounds.
During the past five years there have been remarkable advances
across several technologies thatwill enhance gliomadiscovery research,
including: 1) improved cellularmodels and stem cell culture conditions
(iPS cell, neural stem cell and glioma stem cells), 2) CRISPR/Cas genome
editing, and 3) cell phenotypic screening platforms. The emergence of
these technologies, paralleled by improved understanding of cancer ge-
netic and epigenetic disruptions, should drive development of novel pa-
tient-derived cellular models that can be channelled into cell-based
chemical and genetic screens in vitro and xenotransplantation models
in vivo. Herewe discuss each of these areas, particularly how they inter-
sect andmight be deployed in the coming years to improve the progno-
sis for people living with GBM – one of the most lethal human cancers.
We focus on chemical screens using patient-derived cellular models,
and the opportunities for gene editing to underpin novel cell-based
phenotypic assays. Use of CRISPR/Cas for genetic screens has been
discussed elsewhere (Agrotis and Ketteler, 2015).
2. Sources of neural stem and progenitor cells
Much effort has been expended over the past few decades by devel-
opmental neurobiologists seeking to define the diversity of neural stem
and progenitor cell types responsible for construction of the mammali-
an central nervous system (CNS) (Gage and Temple, 2013). Knowledge
of mammalian brain development has largely come from studies of
mouse developmental biology and several distinct categories of neural
progenitor cells have been identified. The most primitive and earliest-
born neural progenitors are termed neuroepithelial cells, and these like-
ly retain the potential to differentiate into a variety of neuronal or glial
subtypes. Neuroepithelial cells transit at the onset of neurogenesis
into what are now termed apical progenitors (formerly radial glia)
that generate neurons, and at later foetal stages glial cells (Taverna et
al., 2014). These apical progenitors generate the wave of newborn neu-
ronal populations, but do so via stepwise transitions along a series of
distinct intermediate progenitors (Rowitch and Kriegstein, 2010).
These major temporal transitions in neural progenitor states/subtypes
are superimposed by well-understood patterning events that establish
distinct positional identity: e.g. forebrain versus spinal cord, or cortex
versus striatum. In the adultmouse brain, two regions have been uncov-
ered in which new neurons are generated throughout adulthood: the
hippocampus, and thewalls of the forebrain ventricles. A subpopulation
of apical progenitors are the founders of adult neural stem cells and
these emerge postnatally (Merkle et al., 2004). The reader is pointed
to other reviews which cover these topics in more detail (Bond et al.,
2015; Kriegstein and Alvarez-Buylla, 2009).
Despite this progress, we still lack a comprehensive understanding
of the full diversity of distinct immature populations and their differen-
tiation potential and plasticity. New classes of progenitor are still being
uncovered in the mouse (Pilz et al., 2013). Also, inevitably our under-
standing of the diversity of human neural stem and progenitors has
lagged behind that of the mouse, and important species differencesPlease cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1are now being uncovered in the repertoire of progenitors and their mo-
lecular regulation (Florio et al., 2015; Lui et al., 2011, 2014).
Considerable attention has focussed on the developing cortex, due to
its importance in human biology and evolution, and a population of pro-
genitors termed outer radial glia have been described that are thought
to drive the massive expansion of the human (but not mouse) cortical
surface area (Hansen et al., 2010). Application of single cell tran-
scriptome analysis and epigenetic profiling are now providing a more
complete picture of the full range of distinct cell types (Johnson et al.,
2015). Open access databases such as Allen Brain Atlas that integrate
neuroanatomical and gene expression datasets also provide a wealth
of information to understand the genetic and cellular basis of CNS devel-
opment inmouse and human (Miller et al., 2014).More recently a relat-
ed effort has been established for GBM (Sunkin et al., 2013). Altogether
these ongoing efforts should eventually lead to comprehensive under-
standing of the gene expression signatures that define the full inventory
of distinct neural progenitors.
Pluripotent stem cells (PSCs) – embryonic stem cells (ESCs) and in-
duced PSCs (iPSCs) – are phenotypically similar to the early pre-gastru-
lation stage human embryo, and therefore provide a valuable tool to
explore early humandevelopment. Importantly, they also have practical
value as a means to produce human neural cell types in the laboratory
(Dolmetsch and Geschwind, 2011; Pourquié et al., 2015), providing a
potentially unlimited source of neurons and glia that can be utilized in
chemical and genetic screening.
Our knowledge of neural development has been useful to guide ap-
proaches to generate, expand and differentiate neural stem cells in vitro
(Aboody et al., 2011). Neuroepithelial cells emerge early during ES and
iPS cell differentiation – mirroring the primitive ectoderm to neural ec-
toderm developmental transition; these then transit into radial glia/api-
cal progenitors that lose epithelial features such as expression of the
cell-cell tight junction marker ZO-1 and acquire a ‘rosette’-like appear-
ance in culture (Elkabetz et al., 2008). These in turn go on to differenti-
ate into neurons, and then a later wave of glial differentiation
(astrocytes and oligodendrocytes).
It has proven difficult to capture the more primitive neuroepithelial
cells and expand them long term. However, mouse or human radial
glia-like apical progenitors, whether derived from PSC differentiation, or
freshly isolated foetal/adult CNS tissue, can be expanded long-term in cul-
ture using the growth factors EGF and FGF-2. These neural stem cells –
herein termed ‘NS cells’ – can be propagated either in suspension culture
as ‘neurospheres’, or using adherent monolayer. The advantages and dis-
advantages of these in vitro models have been discussed previously else-
where (Pastrana et al., 2011). NS cells are somewhat restricted in their
differentiation capacity and are glial biased, with features more akin to
proliferative adult SVZneural stemcells. It remains unclear towhat extent
distinct positional and temporal identities are permanently erased by the
culture environment, or if some epigeneticmemory of their original iden-
tity persists. The rest of this article focuses on these NS cell cultures. This
cell state most closely corresponds to the glioma stem cells in their pat-
terns of marker expression, glial differentiation bias and requirement for
EGFR signaling. Comparisons of NS cells with their malignant GNS cell
counterparts can identify tumour-associated pathways.
3. Neural stem cells and brain cancer
Around 10 years ago there was increased interest in the relationship
between neural development, neural stem cells and cancer biology. It
became clear that many neural stem cell markers were frequently
expressed in and required for growth of gliomas, such as OLIG2 (Ligon
et al., 2004, 2007). This raised a related issue ofwhether CNS derived tu-
mours might arise from stem cells gone awry, and whether these puta-
tive cancer stem cells are critical to sustaining tumour growth (Stiles et
al., 2008). Functional data supporting a hierarchy of tumour cell malig-
nancy came via improved methods for fractionating tumour popula-
tions based on neural stem cell markers and interrogating theirg discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
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mours may therefore be a ‘caricature’ of the normal tissue stem cell, as
was proposed in the 1960s for tertatocarcinoma (Pierce and Speers,
1988). Thus, gliomas might not be viewed simply as corrupted prolifer-
ative astrocytes, but insteadmay depend upon, and exploit, the core ap-
paratus used by radial glia-like neural stem cells.
There has been much debate and discussion regarding the signifi-
cance of cancer stem cell-basedmodels for understanding cancer biolo-
gy and guiding therapeutic strategies (Kreso and Dick, 2014). Arguably
the most critical question for GBM is whether the putative cancer stem
cells are hijacking and exploiting the self-renewal pathways that under-
pin normal neural stem cell self-renewal, as this information could
eventually be exploited to halt tumour growth and relapse after thera-
py. Indeed, many of the essential transcriptional and epigenetic regula-
tors of neural stem cells are highly expressed in gliomas and have clear
functional importance in sustaining tumour growth (Gallo et al., 2013;
Gangemi et al., 2009; Ligon et al., 2007; Verginelli et al., 2013).
Importantly, those culture conditions widely deployed for the propa-
gation of neural stem cells (serum-free media with EGF and FGF-2)Fig. 1. Sources and diversity of primary cell lines. Cells in red are cancerous, blue cells are neural
development and disease. All resulting cell lines can be cultured for screening purposes under
Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1proved extremely well-suited to expansion of patient-derived putative
glioma stem cells (Galli et al., 2004; Lee et al., 2006; Singh et al., 2003).
Thus, these tumour-initiating cells can be expanded readily while
retaining tumour-initiating capacity. They can also be propagated in ad-
herent monolayer, simplifying chemical and genetic screening (Hubert
et al., 2013; Pollard et al., 2009; Wurdak et al., 2010). Gliomas are there-
fore one of the few human cancers for which we can isolate, culture,
andmanipulate primary cancer stem cells, as well as their ‘normal’ tissue
stem cell counterparts (NSCs). Comparing and contrasting glioma stem
cells with their genetically and epigenetically normal NS cell counterparts
will therefore help to identify potential cancer-specific vulnerabilities.
4. Patient-derived cellular models and matched controls: a unique
opportunity for gliomas
Recurrent genetic and epigenetic perturbations in glioma have now
been extensively catalogued (Brennan et al., 2013; Sturm et al., 2012).
Functional genetic analyses in relevant human preclinical models are
now needed. There have been recent reports of the exploitation of iPSstem cells free from disease. Each cell type gives an orthogonal view of neural stem cells in
identical growth conditions allowing direct comparisons of screening results.
g discovery: Convergence of patient-derived models, genome editing
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4 E. O'Duibhir et al. / Molecular and Cellular Neuroscience xxx (2016) xxx–xxxcells to engineer oncogenic events prior to neural differentiation, there-
by providing a model to interrogate glioma associated mutations across
a range of regional and temporal human progenitors (Funato et al.,
2014; Sancho-Martinez et al., 2016).
A complementary approach to iPSC engineering is to work with pri-
mary foetal and adult derived NS cell lines. Indeed, many groups have
now developed large collections of GSC and NS cell lines that can be
used in both basic and translational projects (Xie et al., 2015). Primary
human NS cells provide the genetically normal controls for functional
studies and comparison with glioma stem cell cultures (Fig. 1). Primary
NS cells from foetal forebrain, midbrain and hindbrain tissues (typically
fromweek 7 to 14 human embryos)will likely be very useful formodel-
ling paediatric GBM and assessing how regional identity influences the
competence to respond to particular gliomamutations. Adult humanNS
cell lines, derived from essentially healthy donors (CNS material from
epilepsy surgery), aremore difficult to establish, but there have been re-
ports of successful cultures established from adult forebrain SVZ (Sanai
et al., 2004). In the coming years these cellular models will help us to
study the origins of GBM and how their spatial and temporal diversity
influences the response to oncogenic insults.
One of the limitations of functional cellular genetic studies in human
iPS cells has been cell line variations, in part due to their diverse genetic
backgrounds. Isogenic matched cell line pairs, where the only genetic
difference is at candidate gene/locus of interest provide the most rigor-
ous controls to draw meaningful conclusions. Similarly, for GSCs it
would be valuable to generate NS cells that are isogenic to original pa-
tient tumour cell of origin. There is in fact a good opportunity to do
this, as iPS cells can be differentiated intoNS cells in vitro, and compared
to the patient tumour-derived GSCs. Such isogenic matched cell lines
will be essential as high quality genetic controls (Fig. 1). These sets of
patient-derived models and their normal genetically matched controls
should also be amenable to genome editing, opening up opportunities
to engineer glioma mutations.
5. Genome editing to engineer normal andglioma-derived stemcells
Engineering precise genetic changes into themouse genome of PSCs
using gene targeting has been the gold standard approach to exploreFig. 2. A genome editing ‘toolkit’ for functional genetic studies and novel engineered cellular m
into normal NSCs (middle) using CRISPR/Cas9 provides both a means for proving mutation cau
variety of useful engineered alleles such as live cell reporters and safe-harbours (right) rem
potentially druggable driver mutations with isogenic non-tagged controls provides an ideal int
Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1cancer gene function and creation of genetically engineered mouse
models (GEMMs). Standard gene targeting approaches involve genera-
tion of a targeting vector and delivery to PSCs by in vitro transfection
and subsequent selection of rare clonal lines with the desired change.
However, this is often time-consuming and requires significant exper-
tise. CRISPR/Cas technologies have caused tremendous excitement
acrossmany areas of life sciences andmedicine, as these designer nucle-
ases enable site-specific engineering of the genome in a much more ef-
ficient manner – including efficient editing of the human genome in iPS
cells.
A unique opportunity has arisen to deploy these technologies for
new drug development for GBM, across several areas: first, identifica-
tion of new molecular targets through genome-wide CRISPR screens
(Hart et al., 2015; Munoz et al., 2016; Toledo et al., 2015); second, engi-
neering of candidate drivermutations into normal NS cells; third, rever-
sion of genetic drivers to wild-type in GSCs; fourth, creation of useful
live cell reporters (epitope tags or fluorescent proteins) or biosensors
for cell based phenotypic screening.
NSCs and GSCs are easily transfected, expandable and clonogenic
and should be well suited to genome editing. We have recently found
that CRISPR/Cas-based genetic editing is straightforward in NSC and
GSC lines (Pollard lab, submitted). It is therefore now possible to effi-
ciently introduce targeted and sophisticated genetic changes such as:
specific insertion/deletions; introduction of somatic point mutations;
gene targeting to introduce conditional alleles, replace exons or modify
cis-regulatory elements; knock-in of fluorescent marker gene reporters
and biochemical tags; and engineering of large-scale chromosome
structural engineering (e.g. large focal amplifications or deletions)
(Fig. 2). Thus, it will be possible to construct a whole suite of useful iso-
genic human cellular model and reporter cell lines.
The combination of improvedmethods for isolating and propagating
normal human NS cell lines as well as their glioma-derived malignant
counterparts, alongside these remarkable developments in genome
editing, is opening up prospects for development of new therapeutics
for GBM. The gene editing pipelinewould allow identification of drivers
that could be targeted via existing or newly developed small molecules.
Moreover, GBM stem cell cultures and matched controls – along with
associated knock in fluorescent markers of stem cell and differentiationodels. Reversion of candidate drivers to wild-type (left) and/or introduction of key drivers
sality, and matched cell lines as perfect isogenic controls for drug screening. Creation of a
oves need for fluorescent staining. Co-culture of fluorescently tagged cell lines carrying
ernally controlled cell assay.
g discovery: Convergence of patient-derived models, genome editing
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Fig. 3.High Content Screening approach and hit interpretation. Cell lines can be co-cultured or screened in parallel. Compound effects common to all cell lines are nonspecific while effects
found in only one line are cancer or mutation specific. ‘Effects’ can be found in a wide variety of cell and nuclear morphologies at selected time points given the multiparametric nature of
high content screening. Iterative rounds of genome engineering can be used to verify drug targets and determine mechanism of action. These phenotypic screens provide richer
information; but are more difficult to implement than biochemical assays used in target based drug discovery.
5E. O'Duibhir et al. / Molecular and Cellular Neuroscience xxx (2016) xxx–xxxstate – could be used directly in cell based phenotypic screens. The gene
editing pipeline described above would also be instrumental for valida-
tion of drug specificity (Fig. 3). Thus,we cannowenvisagemoving into a
new era of sophisticated genetic analysis in primary human cells – both
normal NS and glioma-derived NS cells. Some specific examples are de-
scribed below.
5.1. Engineering of oncogenes and tumour suppressors
Tumours often develop progressively through preneoplastic growth,
to full malignant transformation and undergo further evolution under
the selective pressure associated with treatments. Deciphering what
are true drivers from passenger mutations is critical to define the best
therapeutic targets. Thus, to make rapid progress towards novel thera-
pies, efforts should be focused on deletion of themost frequently ampli-
fied oncogenes thought to drive the disease (EGFR, PDGFR, CDK4).
Complementary studieswould aim to revertmutant towild-type alleles
for TP53, H3F3A, TERT (promoter) and IDH1/2. Additionally, using the
matched genetically normal isogenic controls from the same patient
(iPS-derived NSCs) glioma mutations can be engineered stepwise and
in combination (Fig. 2). Together, this strategy should provide the
gold standard genetically defined cellular models for chemical screens.
5.2. Knock in reporter cell lines
In parallel to exploring drivermutations it should be possible to per-
form knock in of useful reporters or other cargos to the safe-harbour
AAVS1 locus (the AAVS1 is equivalent to the ROSA26 locus in mouse).
For example, in a simple scenario, knock in of a constitutive eGFP and
Luciferase labelled expression cassette would be extremely useful for
tracking xenograft growth in live animals using small animal imaging
with a bioluminescence or intravitral imaging system. This overcomes
the issue of stable transfection via lentivirus, and removes issues of si-
lencing: a persistent problem when using random insertion
transgenesis. Introduction of eGFP, mCherry or BFP2, fluorescent re-
porters under the control of a variety of endogenous gene promoters
(SOX2, FOXG1, OLIG2) also provides useful live cell reporters tomonitorPlease cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1‘stemness’ and conversely differentiation (AQP4, CNPase, NFM; for as-
trocyte, oligodendrocyte and neuron, respectively). These lineage re-
porters have great utility in vitro for high content phenotypic screening.
6. Cell-based phenotypic screening
Phenotypic screening can be defined as the quantification of func-
tional biological endpoints from physiological-basedmodel systems fol-
lowing exposure to libraries of small molecule chemicals, gene-
targeting perturbations or proteins/antibodies (Lee and Berg, 2013;
Yarrow et al., 2003; Carragher, 2008). This is particularly useful in
stem cell based models where cell heterogeneity and shifts in differen-
tiation status mean individual cell behavior must be tracked.
Phenotypic screening is typically performed with cell-based assays
ormodel organisms amenable to automatedmedium- to high-through-
put screening platforms. Smaller focused phenotypic screens using high
quality tool compound libraries (see Box 1) can also be employed to de-
termine which pathways are involved in a particular process.
In contrast to the widely adopted target-directed drug discovery
(TDD)model, inwhich screening is directed upon a pre-nominated pro-
tein target, phenotypic drug discovery (PDD) does not depend on prior
knowledge of molecular targets (Fig. 4). PDD can also be applied to the
discovery of novel drug combinations, or to support disease reposi-
tioning by screening approved drug libraries (Dawson and Carragher,
2014; Reaume, 2012). In contemporary drug discovery projects pheno-
typic screens are typically placed as secondary screening assays to con-
firm the quality and physiological relevance of novel antagonists or
agonists derived from high throughput biochemical or structure-based
screening. By placing phenotypic screening at the beginning of the
drug discovery paradigm however it is possible to identify new targets
or novel small molecules for further investigation.
The emergence of newmolecular biology techniques, such as genome
sequencing and more in-depth understanding of genetic linkage with
human disease, has led to TDD being preferred drug discovery strategy
by both the biopharmaceutical industry and core academic drug discov-
ery groups. However, the anticipated increase in clinical approval rates
of novel first-in-class therapies has not followed, indeed, the exponentialg discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
Box 1
High quality commercially available and open source tool compound
libraries.
(Brown and Müller, 2015; Drewry et al., 2014; Elkins et al., 2015; Mei
et al., 2014; Moisan et al., 2015)
6 E. O'Duibhir et al. / Molecular and Cellular Neuroscience xxx (2016) xxx–xxxincrease in investment in reductionist TDD strategies has coincided with
an overall decline in R&D productivity (Paul et al., 2010; Scannell et al.,
2012). Cancer has been highlighted as a fruitful area for modern TDD
strategies (Hoelder et al., 2012), however, cancer subtypes which do not
fall intowell-definedmolecular subtypes remain intractable to new treat-
ments derived fromboth strategies. This is particularly apparent in glioma
where there have been no advances in effective targeted molecular ther-
apies. The minimal impact of TDD strategies on the most serious cancers,
including gliomas is of serious concern.
The rapid evolution and convergence of new technologies, including
advances in image-based phenotypic screening, iPSC technologies andFig. 4. Proposal for a streamlined drug discovery process based on phenotypic screening. Fr
emphasised. This is in contrast to the brute force massively high quantity screening in traditio
Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1gene editing, arewell placed to advance a new era ofmodern phenotyp-
ic screening in cell-basedmodels of disease. Thewidespread use of basic
phenotypic screening assays applied to established cell lines, which
poorly model disease, most likely underestimates the true impact that
PDD strategies will have. Furthermore, the development of more infor-
mative phenotypic screening across more disease relevant cell models
plays a major role in enhancing TDD by supporting more robust target
validation and secondary screening assay cascades. We propose that
further development and increased adoption of the latest advances in
image-based phenotypic screening, patient-derived primary cell
models, iPSC and genome editing should have a significant impact in
identifying new hits and leads for GBM. Clearly TDD and PDD represent
complementary approaches and both have their value in the drug dis-
covery effort. PDD involves increased effort and costs (labour and re-
agent costs) in acquiring large amounts of imaging data and lower
throughput compared to TDD. However, for primary GBM clear-cut
therapeutic target hypothesis and robust validation of novel molecular
targets, which could be drivers across all the disease subtypes, have
not emerged. Consequently an unbiased PDD approach is therefore par-
ticularly appealing, as unexpected pathways and biology can emerge, as
recently exemplified by the study of Kitambi et al. (Kitambi et al., 2014).7. Advances in image-based phenotypic screening
Microscopy has a long established role in the history of scientific re-
search and represents a cornerstone of cell biology and pathology. Tradi-
tionally, microscopic imaging has been applied manually across small
sample numbers to provide subjective evaluation of cell behavior and in
vivo physiology. Robotic automation of microscope operation and
associated phenotypic assays (e.g. immunocytochemistry protocols) is
currently transforming the field of microscopy towards higher through-
put andmorequantitative applications (seeBox2 for anoverviewof com-
mercially available high content imaging systems). Significant advances
have also been made in optical performance, fluorescent reporter mole-
cules, image-analysis and image-informatics, High content analysis of
multiparametric features extracted fromfluorescent or brightfield images
of cells, tissues or small-model organisms is now possible (Taylor et al.,
2001) providing quantitative readouts of phenotypic traits.
These developments have also supported higher throughput appli-
cation of phenotypic screening to large chemical libraries, whole ge-
nome arrayed si/shRNA libraries, dose-matrix combination screening
and comparison of phenotypic response across genetically distinct cell
panels (Caie et al., 2010; Dawson and Carragher, 2014; Neumann et
al., 2006; Yarrow et al., 2003). A significant advantage in high-contentom the beginning and at each step during PDD assay quality and biological relevance is
nal TDD pipelines.
g discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
Box 2
Overview of available image based phenotypic screening technologies.
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the extraction of functional data points with high spatial resolution
across X, Y and Z dimensions, allowing meaningful screening assays to
be conducted in more complex multicellular and 3D models (Wenzel
et al., 2014).8. Live-cell kinetic imaging
Integration of robust atmospheric and temperature control of
biological samples mounted within high-content screening platforms,
together with the development of novel optical biosensors and fluores-
cent reporter constructs, have increased the scope of phenotypic
screening to include live-cell kinetic imaging (Isherwood et al., 2011).
These approaches inevitably push resource limits in terms of assay de-
velopment timelines and computational power required for image stor-
age and analysis. So they are difficult to scale to high throughput
screening (tens of thousands of compounds). Nevertheless, they pro-
vide extremely rich phenotypic information, and critical kinetic and
spatial information, which may have greater value in hit selection and
validation of compounds or the dose-response assays, for example to
capture cellular transitions during differentiation; differentiation thera-
py is one potential strategy to limit cancer stem cell self-renewal which
is being explored. Developments in the design of compact automated
imaging platforms, which can be placed inside an environmental cham-
ber (IncuCyte-Zoom™; Cell-IQ® and Biostation CT, see Box 2) and inte-
grated with external and internal plate handling robotics further
supports longer-term kinetic cellular assays across multiwell plates
within a stably controlledmicroenvironment at scale. Long-termkineticPlease cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1imaging and phenotypic screening can thus be performed under de-
fined environmental conditions, for example normoxia or hypoxia,
whichmaymore accurately reflect the physiology and pathophysiology
of tissues in vivo.
Kinetic analysis of cell phenotype following exposure to chemicals can
reveal unique insights into cellular pharmacology,which are not apparent
from traditional fixed endpoint assays. For example, cell physiological
processes that operate under precise temporal and spatial control such
as cell-cycle transition, motility, cell death, cell signaling and subcellular
trafficking of proteins including oscillatory nuclear-to-cytoplasmic trans-
locations can only reliably be recorded by kinetic analysis of live cells.
Long-term image-based kinetic analysis of cell phenotypes facili-
tates quantification of stem cell differentiation and cell fate. Such
image-based live cell phenotypic screening studies can be applied to
discovermodulators which accelerate or delay stem cell differentiation.
Our groups have utilized such live cell imaging to probe small chemical
libraries for effects on both NS and GNS cells (Danovi et al., 2010, 2013;
Pollard et al., 2009). Kinetic analysis of phenotypic response further
supports the selection of the most informative and appropriate time-
points for higher throughput endpoint assays. This may include the se-
lection of the most optimal time-point or time-points to measure tran-
sient phenotypic response or selection of earliest time-point/
phenotypic measure predictive of long-term stem cell fate to accelerate
stem cell screening studies. Thus, while the throughput is reduced, the
potential for obtaining rich biological information is immense. This
will guide assay development, hit selection and inform subsequent
drug discovery and development strategy.
9. Multiparametric phenotypic profiling
Traditional cell-based phenotypic screening assays depend upon
simple cell viability or genetic reporter readouts, and therefore provide
limited information on drugmechanism-of-action to guidehit selection.
Such basic phenotypic assays also provide limited opportunity to direct
structural activity relationships (SAR) and guide chemical design to-
wards precise phenotypes representing enhanced efficacy and safety
features. These are important issues to address.
The evolution of multiparametric phenotypic assays combined with
multivariate statistics and a variety of new image-informatics methods
have produced the discipline of phenotypic profiling. Phenotypic profil-
ing enables the classification of phenotypic response and thus com-
pound mechanism-of-action based upon similar multiparametric
phenotypic fingerprints (Carpenter et al., 2006; Feng et al., 2009;
Perlmanet al., 2004; Tanaka et al., 2005a). The application of phenotypic
profiling and image-informatics methods incorporating machine learn-
ing and artificial neural networks has steadily evolved to support robust
phenotypic profiling across distinct cell types (Caie et al., 2010; Ljosa et
al., 2013; Smith and Horvath, 2014). A key requirement of image infor-
matics methods applied to multiparametric high content data sets is a
minimal number of measured features with retention of maximal phe-
notypic information. Feature reduction methods including principal
component analysis, factor analysis and support vector machines have
been commonly used to distil multiparametric high content data to sin-
gle endpoints, which can be used to rank compound performance and
integrate phenotypic response with orthogonal datasets (Ljosa et al.,
2013; Tanaka et al., 2005b). Phenotypic data reduction to single end-
points supports the association of biological similarity with chemical
similarity to guide chemical design and direct SAR from phenotypic re-
sponse (Young et al., 2007).
10. Cheminformatics and chemical library design for phenotypic
screening
Phenotypic profiling methods have also been combined with
cheminformatics approaches to further guide chemical design based
on phenotypic data and development of themost appropriate chemicalg discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
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2009; Wawer et al., 2014). While the methods for defining chemical
similarity and linking chemical structure to phenotypic response data
are still evolving, chemical features associated with frequent ‘hits’ in
multiple diverse cell-based assays representing ‘non-specific’ pheno-
typic outcomes can be identified and interpreted appropriately
(Tanikawa et al., 2009). Alternatively, compounds with distinct chemi-
cal features which produce similar biological phenotypes might be con-
sidered starting points for new library synthesis directed at specific
phenotypic outcomes.
The development of publicly available cheminformatics databases,
combined with commercially available chemically diverse libraries
and annotated compounds, supports further advancement of
phenotypic screening (see Box 1 for links to further information on
these resources). Specifically, custom-designed phenotypic toolbox
compounds, which provide a reference library for classifying themech-
anism-of-action of unknown compounds, continue to be developed and
expanded. Such development supports the expansion of phenotypic
screening beyond large pharma into small biotech and academic trans-
lational research groups.
11. The road ahead: linking phenotype with genotype to advance
pharmacogenomics studies in glioma
Application of high content screening across genetically distinct cell
lines can help elucidate drug mechanism-of-action and guide clinical po-
sitioning by linking phenotype to genotype (Johannessen et al., 2015).
Transcriptional profiling of well-characterized cancer cell-line panels
such as the NCI-60 collection has supported such studies. Correlation of
the NCI-60 transcriptional profiles with phenotypic response to com-
pound treatments using existing cell viability assay results produced
over 200 gene expression based signatures for compound sensitivity
(Staunton et al., 2001). These early results provided the impetus for ex-
pansion of high throughput pharmacogenomics studies across larger can-
cer cell line panels including a study led by the Sanger Institute across 639
cancer cell lines and a separate study led by the Broad Institute in collab-
oration with Novartis across 949 cell lines (Barretina et al., 2012; Garnett
et al., 2012). Both studies used a simple cell viability assay readout for re-
cording phenotypic response and quantification of drug sensitivity.
Comparative analysis of both studies revealed inconsistencies
(Haibe-Kains et al., 2013; Stransky et al., 2015). Some of this may be at-
tributed to the use of transformed cell lines, which are often genetically
unstable and no longer represent the primary cells and tissues from
which theywere originally derived. Also the simplewholewell cell viabil-
ity endpoint employed in these studies lacks precisemechanistic informa-
tion. The advances in precise gene editing technologies such as CRISPR/
Cas can provide genetically defined models representative of a wider va-
riety of glioma subtypes. These cell lines can be used to precisely quantify
and classify cell phenotype (Shalem et al., 2014). The convergence of
gene-editingwith iPSC andhigh content phenotypic screening further en-
able the expansion of high throughput pharmacogenomics studies from
simple cell viability endpoints to more complex phenotypes and assay
formats which can help define new targets for glioblastoma.
In summary, frontloading cell based phenotypic models of glioma at
the earliest stages of the drug discovery using disease relevant cellular
modelswill fast track the identification of themost promising therapeu-
tic targets and candidate drugs. The rationale outlined here represents
our perspectives on how these new technologies are opening up drug
pipelines that will hopefully lead to new drugs and improved clinical
outcomes for glioma patients.
Acknowledgements
SMP is supported by a Cancer Research UK Senior Research Fellow-
ship (A19778). We thank Faye Robertson, Gillian Morrison and Paul
Brennan for helpful comments on the manuscript.Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1References
Aboody, K., Capela, A., Niazi, N., Stern, J.H., Temple, S., 2011. Translating stem cell studies
to the clinic for CNS repair: current state of the art and the need for a Rosetta stone.
Neuron 70:597–613. http://dx.doi.org/10.1016/j.neuron.2011.05.007.
Agrotis, A., Ketteler, R., 2015. A new age in functional genomics using CRISPR/Cas9 in
arrayed library screening. Front. Genet. 6:1111. http://dx.doi.org/10.3389/fgene.
2015.00300.
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J.,
Lehár, J., Kryukov, G.V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M.F.,
Monahan, J.E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F.A.,
Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I.H., Cheng, J., Yu, G.K.,
Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M.D., Wang, L., Hatton, C.,
Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R.C., Liefeld, T.,
MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J.P., Gabriel, S.B., Getz, G.,
Ardlie, K., Chan, V., Myer, V.E., Weber, B.L., Porter, J., Warmuth, M., Finan, P., Harris,
J.L., Meyerson, M., Golub, T.R., Morrissey, M.P., Sellers, W.R., Schlegel, R., Garraway,
L.A., 2012. The cancer cell line encyclopedia enables predictive modelling of antican-
cer drug sensitivity. Nature 483. http://dx.doi.org/10.1038/nature11003 (603–307).
Bond, A.M., Ming, G.-L., Song, H., 2015. Adult mammalian neural stem cells and
neurogenesis: five decades later. Cell Stem Cell 17:385–395. http://dx.doi.org/10.
1016/j.stem.2015.09.003.
Brennan, C.W., Verhaak, R.G.W., McKenna, A., Campos, B., Noushmehr, H., Salama, S.R.,
Zheng, S., Chakravarty, D., Sanborn, J.Z., Berman, S.H., Beroukhim, R., Bernard, B.,
Wu, C.-J., Genovese, G., Shmulevich, I., Barnholtz-Sloan, J., Zou, L., Vegesna, R.,
Shukla, S.A., Ciriello, G., Yung, W.K., Zhang, W., Sougnez, C., Mikkelsen, T., Aldape,
K., Bigner, D.D., Van Meir, E.G., Prados, M., Sloan, A., Black, K.L., Eschbacher, J.,
Finocchiaro, G., Friedman, W., Andrews, D.W., Guha, A., Iacocca, M., O'Neill, B.P.,
Foltz, G., Myers, J., Weisenberger, D.J., Penny, R., Kucherlapati, R., Perou, C.M., Hayes,
D.N., Gibbs, R., Marra, M., Mills, G.B., Lander, E., Spellman, P., Wilson, R., Sander, C.,
Weinstein, J., Meyerson, M., Gabriel, S., Laird, P.W., Haussler, D., Getz, G., Chin, L.,
Research Network, T.C.G.A., 2013. The somatic genomic landscape of glioblastoma.
Cell 155:462–477. http://dx.doi.org/10.1016/j.cell.2013.09.034.
Brown, P.J., Müller, S., 2015. Open access chemical probes for epigenetic targets. Future
Med. Chem. 7:1901–1917. http://dx.doi.org/10.4155/fmc.15.127.
Caie, P.D., Walls, R.E., Ingleston-Orme, A., Daya, S., Houslay, T., Eagle, R., Roberts, M.E.,
Carragher, N.O., 2010. High-content phenotypic profiling of drug response signatures
across distinct cancer cells. Mol. Cancer Ther. 9:1913–1926. http://dx.doi.org/10.
1158/1535-7163.MCT-09-1148.
Carpenter, A.E., Jones, T.R., Lamprecht, M.R., Clarke, C., Kang, I.H., Friman, O., Guertin, D.A.,
Chang, J.H., Lindquist, R.A., Moffat, J., Golland, P., Sabatini, D.M., 2006. CellProfiler:
image analysis software for identifying and quantifying cell phenotypes. Genome
Biol. 7:R100. http://dx.doi.org/10.1186/gb-2006-7-10-r100.
Carragher, N.O., 2008. Profiling distinct mechanisms of tumour invasion for drug discov-
ery: imaging adhesion, signalling and matrix turnover. Clin. Exp. Metastasis 26:
381–397. http://dx.doi.org/10.1007/s10585-008-9222-y.
Danovi, D., Falk, A., Humphreys, P., Vickers, R., Tinsley, J., Smith, A.G., Pollard, S.M.,
2010. Imaging-based chemical screens using normal and glioma-derived neural
stem cells. Biochem. Soc. Trans. 38:1067–1071. http://dx.doi.org/10.1042/
BST0381067.
Danovi, D., Folarin, A., Gogolok, S., Ender, C., Elbatsh, A.M.O., Engström, P.G., Stricker, S.H.,
Gagrica, S., Georgian, A., Yu, D., U, K.P., Harvey, K.J., Ferretti, P., Paddison, P.J., Preston,
J.E., Abbott, N.J., Bertone, P., Smith, A., Pollard, S.M., 2013. A high-content small mol-
ecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like
kinase 1. PLoS ONE 8, e77053. http://dx.doi.org/10.1371/journal.pone.0077053.
Dawson, J.C., Carragher, N.O., 2014. Quantitative phenotypic and pathway profiling guides
rational drug combination strategies. Front. Pharmacol. 5:118. http://dx.doi.org/10.
3389/fphar.2014.00118.
Dolmetsch, R., Geschwind, D.H., 2011. The human brain in a dish: the promise of iPSC-de-
rived neurons. Cell 145:831–834. http://dx.doi.org/10.1016/j.cell.2011.05.034.
Drewry, D.H., Willson, T.M., Zuercher, W.J., 2014. Seeding collaborations to advance ki-
nase science with the GSK Published Kinase Inhibitor Set (PKIS). Curr. Top. Med.
Chem. 14:340–342. http://dx.doi.org/10.2174/1568026613666131127160819.
Elkabetz, Y., Panagiotakos, G., Al Shamy, G., Socci, N.D., Tabar, V., Studer, L., 2008. Human
ES cell-derived neural rosettes reveal a functionally distinct early neural stem cell
stage. Genes Dev. 22:152–165. http://dx.doi.org/10.1101/gad.1616208.
Elkins, J.M., Fedele, V., Szklarz, M., Abdul Azeez, K.R., Salah, E., Mikolajczyk, J., Romanov, S.,
Sepetov, N., Huang, X.-P., Roth, B.L., Zen, H., Al, A., Fourches, D., Muratov, E., Tropsha,
A., Morris, J., Teicher, B.A., Kunkel, M., Polley, E., Lackey, K.E., Atkinson, F.L.,
Overington, J.P., Bamborough, P., Müller, S., Price, D.J., Willson, T.M., Drewry, D.H.,
Knapp, S., Zuercher, W.J., 2015. Comprehensive characterization of the Published Ki-
nase Inhibitor Set. Nat. Biotechnol. 34:95–103. http://dx.doi.org/10.1038/nbt.3374.
Feng, Y., Mitchison, T.J., Bender, A., Young, D.W., Tallarico, J.A., 2009. Guide to drug discov-
ery: multi-parameter phenotypic profiling: using cellular effects to characterize
small-molecule compounds. Nat. Rev. Drug Discov. 8:1–12. http://dx.doi.org/10.
1038/nrd2876.
Florio, M., Albert, M., Taverna, E., Namba, T., Brandl, H., Lewitus, E., Haffner, C., Sykes, A.,
Wong, F.K., Peters, J., Guhr, E., Klemroth, S., Prüfer, K., Kelso, J., Naumann, R.,
Nüsslein, I., Dahl, A., Lachmann, R., Pääbo, S., Huttner, W.B., 2015. Human-specific
gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion.
Science 347:1465–1470. http://dx.doi.org/10.1126/science.aaa1975.
Funato, K., Major, T., Lewis, P.W., Allis, C.D., Tabar, V., 2014. Use of human embryonic stem
cells to model pediatric gliomas with H3.3K27M histone mutation. Science 346:
1529–1533. http://dx.doi.org/10.1126/science.1253799.
Gage, F.H., Temple, S., 2013. Neural stem cells: generating and regenerating the brain.
Neuron 80:588–601. http://dx.doi.org/10.1016/j.neuron.2013.10.037.g discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
9E. O'Duibhir et al. / Molecular and Cellular Neuroscience xxx (2016) xxx–xxxGalli, R., Binda, E., Orfanelli, U., Cipelletti, B., Gritti, A., De Vitis, S., Fiocco, R., Foroni, C.,
DiMeco, F., Vescovi, A., 2004. Isolation and characterization of tumorigenic, stem-
like neural precursors from human glioblastoma. Cancer Res. 64:7011–7021. http://
dx.doi.org/10.1158/0008-5472.CAN-04-1364.
Gallo, M., Ho, J., Coutinho, F.J., Vanner, R., Lee, L., Head, R., Ling, E.K.M., Clarke, I.D., Dirks,
P.B., 2013. A tumorigenic MLL-Homeobox network in human glioblastoma stem
cells. Cancer Res. 73:417–427. http://dx.doi.org/10.1158/0008-5472.CAN-12-1881.
Gangemi, R.M.R., Griffero, F., Marubbi, D., Perera, M., Capra, M.C., Malatesta, P., Ravetti,
G.L., Zona, G.L., Daga, A., Corte, G., 2009. SOX2 silencing in glioblastoma tumor-initiat-
ing cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27:40–48.
http://dx.doi.org/10.1634/stemcells.2008-0493.
Garnett, M.J., Edelman, E.J., Heidorn, S.J., Greenman, C.D., Dastur, A., Lau, K.W., Greninger,
P., Thompson, I.R., Luo, X., Soares, J., Liu, Q., Iorio, F., Surdez, D., Chen, L., Milano, R.J.,
Bignell, G.R., Tam, A.T., Davies, H., Stevenson, J.A., Barthorpe, S., Lutz, S.R., Kogera, F.,
Lawrence, K., McLaren-Douglas, A., Mitropoulos, X., Mironenko, T., Thi, H.,
Richardson, L., Zhou, W., Jewitt, F., Zhang, T., O'Brien, P., Boisvert, J.L., Price, S., Hur,
W., Yang, W., Deng, X., Butler, A., Choi, H.G., Chang, J.W., Baselga, J., Stamenkovic, I.,
Engelman, J.A., Sharma, S.V., Delattre, O., Saez-Rodriguez, J., Gray, N.S., Settleman, J.,
Futreal, P.A., Haber, D.A., Stratton, M.R., Ramaswamy, S., McDermott, U., Benes, C.H.,
2012. Systematic identification of genomic markers of drug sensitivity in cancer
cells. Nature 483:570–575. http://dx.doi.org/10.1038/nature11005.
Haibe-Kains, B., El-Hachem, N., Birkbak, N.J., Jin, A.C., Beck, A.H., Aerts, H.J.W.L.,
Quackenbush, J., 2013. Inconsistency in large pharmacogenomic studies. Nature
504:389–393. http://dx.doi.org/10.1038/nature12831.
Hansen, D.V., Lui, J.H., Parker, P.R.L., Kriegstein, A.R., 2010. Neurogenic radial glia in the
outer subventricular zone of human neocortex. Nature 464:554–561. http://dx.doi.
org/10.1038/nature08845.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K.R., MacLeod, G., Mis, M.,
Zimmermann, M., Fradet-Turcotte, A., Sun, S., Mero, P., Dirks, P., Sidhu, S., Roth, F.P.,
Rissland, O.S., Durocher, D., Angers, S., Moffat, J., 2015. High-resolution CRISPR
screens reveal fitness genes and genotype-specific cancer liabilities. Cell 163:
1515–1526. http://dx.doi.org/10.1016/j.cell.2015.11.015.
Hoelder, S., Clarke, P.A., Workman, P., 2012. Discovery of small molecule cancer drugs:
successes, challenges and opportunities. Mol. Oncol. 6:155–176. http://dx.doi.org/
10.1016/j.molonc.2012.02.004.
Hubert, C.G., Bradley, R.K., Ding, Y., Toledo, C.M., Herman, J., Skutt-Kakaria, K., Girard, E.J.,
Davison, J., Berndt, J., Corrin, P., Hardcastle, J., Basom, R., Delrow, J.J., Webb, T., Pollard,
S.M., Lee, J., Olson, J.M., Paddison, P.J., 2013. Genome-wide RNAi screens in human
brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 27:
1032–1045. http://dx.doi.org/10.1101/gad.212548.112.
Isherwood, B., Timpson, P., McGhee, E.J., Anderson, K.I., Canel, M., Serrels, A.,
Brunton, V.G., Carragher, N.O., 2011. Live cell in vitro and in vivo imaging appli-
cations: accelerating drug discovery. Pharmaceutics 3:141–170. http://dx.doi.
org/10.3390/pharmaceutics3020141.
Johannessen, C.M., Clemons, P.A., Wagner, B.K., 2015. Integrating phenotypic small-mole-
cule profiling and human genetics: the next phase in drug discovery. Trends Genet.
31:16–23. http://dx.doi.org/10.1016/j.tig.2014.11.002.
Johnson, M.B., Wang, P.P., Atabay, K.D., Murphy, E.A., Doan, R.N., Hecht, J.L., Walsh, C.A.,
2015. Single-cell analysis reveals transcriptional heterogeneity of neural progenitors
in human cortex. Nat. Neurosci. 18:637–646. http://dx.doi.org/10.1038/nn.3980.
Kitambi, S.S., Toledo, E.M., Usoskin, D., Wee, S., Harisankar, A., Svensson, R., Sigmundsson,
K., Kalderén, C., Niklasson, M., Kundu, S., Aranda, S., Westermark, B., Uhrbom, L.,
Andäng, M., Damberg, P., Nelander, S., Arenas, E., Artursson, P., Walfridsson, J.,
Nilsson, K.F., Hammarström, L.G.J., Ernfors, P., 2014. Vulnerability of glioblastoma
cells to catastrophic vacuolization and death induced by a small molecule. Cell 157:
313–328. http://dx.doi.org/10.1016/j.cell.2014.02.021.
Kreso, A., Dick, J.E., 2014. Evolution of the cancer stem cell model. Cell Stem Cell 14:
275–291. http://dx.doi.org/10.1016/j.stem.2014.02.006.
Kriegstein, A., Alvarez-Buylla, A., 2009. The glial nature of embryonic and adult neural
stem cells. Annu. Rev. Neurosci. 32:149–184. http://dx.doi.org/10.1146/annurev.
neuro.051508.135600.
Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L.L., Rich, J.N., 2015. Cancer
stem cells in glioblastoma. Genes Dev. 29:1203–1217. http://dx.doi.org/10.1101/
gad.261982.115.
Lee, J.A., Berg, E.L., 2013. Neoclassic drug discovery: the case for lead generation using
phenotypic and functional approaches. J. Biomol. Screen. 18:1143–1155. http://dx.
doi.org/10.1177/1087057113506118.
Lee, J., Kotliarova, S., Kotliarov, Y., Li, A., Su, Q., Donin, N.M., Pastorino, S., Purow, B.W.,
Christopher, N., Zhang, W., Park, J.K., Fine, H.A., 2006. Tumor stem cells derived
from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype
and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:
391–403. http://dx.doi.org/10.1016/j.ccr.2006.03.030.
Ligon, K.L., Alberta, J.A., Kho, A.T., Weiss, J., Kwaan, M.R., Nutt, C.L., Louis, D.N., Stiles, C.D.,
Rowitch, D.H., 2004. The oligodendroglial lineage marker OLIG2 is universally
expressed in diffuse gliomas. J. Neuropathol. Exp. Neurol. 63, 499–509.
Ligon, K.L., Huillard, E., Mehta, S., Kesari, S., Liu, H., Alberta, J.A., Bachoo, R.M., Kane, M., Louis,
D.N., DePinho, R.A., Anderson, D.J., Stiles, C.D., Rowitch, D.H., 2007. Olig2-regulated line-
age-restricted pathway controls replication competence in neural stem cells and malig-
nant glioma. Neuron 53:503–517. http://dx.doi.org/10.1016/j.neuron.2007.01.009.
Ljosa, V., Caie, P.D., ter Horst, R., Sokolnicki, K.L., Jenkins, E.L., Daya, S., Roberts, M.E., Jones,
T.R., Singh, S., Genovesio, A., Clemons, P.A., Carragher, N.O., Carpenter, A.E., 2013.
Comparison of methods for image-based profiling of cellular morphological re-
sponses to small-molecule treatment. J. Biomol. Screen. 18:1321–1329. http://dx.
doi.org/10.1177/1087057113503553.
Lui, J.H., Hansen, D.V., Kriegstein, A.R., 2011. Development and evolution of the human
neocortex. Cell 146:18–36. http://dx.doi.org/10.1016/j.cell.2011.06.030.Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1Lui, J.H., Nowakowski, T.J., Pollen, A.A., Javaherian, A., Kriegstein, A.R., Oldham, M.C., 2014.
Radial glia require PDGFD-PDGFRβ signalling in human but notmouse neocortex. Na-
ture 515:264–268. http://dx.doi.org/10.1038/nature13973.
Mei, F., Fancy, S.P.J., Shen, Y.-A.A., Niu, J., Zhao, C., Presley, B., Miao, E., Lee, S., Mayoral,
S.R., Redmond, S.A., Etxeberria, A., Xiao, L., Franklin, R.J.M., Green, A., Hauser, S.L.,
Chan, J.R., 2014. Micropillar arrays as a high-throughput screening platform for
therapeutics in multiple sclerosis. Nat. Med. 20:954–960. http://dx.doi.org/10.
1038/nm.3618.
Merkle, F.T., Tramontin, A.D., Garcia-Verdugo, J.-M., Alvarez-Buylla, A., 2004. Radial glia
give rise to adult neural stem cells in the subventricular zone. Proc. Natl. Acad. Sci.
U. S. A. 101:17528–17532. http://dx.doi.org/10.1073/pnas.0407893101.
Miller, J.A., Ding, S.-L., Sunkin, S.M., Smith, K.A., Ng, L., Szafer, A., Ebbert, A., Riley, Z.L.,
Royall, J.J., Aiona, K., Arnold, J.M., Bennet, C., Bertagnolli, D., Brouner, K., Butler, S.,
Caldejon, S., Carey, A., Cuhaciyan, C., Dalley, R.A., Dee, N., Dolbeare, T.A., Facer,
B.A.C., Feng, D., Fliss, T.P., Gee, G., Goldy, J., Gourley, L., Gregor, B.W., Gu, G.,
Howard, R.E., Jochim, J.M., Kuan, C.L., Lau, C., Lee, C.-K., Lee, F., Lemon, T.A.,
Lesnar, P., McMurray, B., Mastan, N., Mosqueda, N., Naluai-Cecchini, T., Ngo, N.-
K., Nyhus, J., Oldre, A., Olson, E., Parente, J., Parker, P.D., Parry, S.E., Stevens, A.,
Pletikos, M., Reding, M., Roll, K., Sandman, D., Sarreal, M., Shapouri, S.,
Shapovalova, N.V., Shen, E.H., Sjoquist, N., Slaughterbeck, C.R., Smith, M., Sodt,
A.J., Williams, D., Zöllei, L., Fischl, B., Gerstein, M.B., Geschwind, D.H., Glass, I.A.,
Hawrylycz, M.J., Hevner, R.F., Huang, H., Jones, A.R., Knowles, J.A., Levitt, P.,
Phillips, J.W., Šestan, N., Wohnoutka, P., Dang, C., Bernard, A., Hohmann, J.G.,
Lein, E.S., 2014. Transcriptional landscape of the prenatal human brain. Nature
508:199–206. http://dx.doi.org/10.1038/nature13185.
Moisan, A., Lee, Y.-K., Zhang, J.D., Hudak, C.S., Meyer, C.A., Prummer, M., Zoffmann, S.,
Truong, H.H., Ebeling, M., Kiialainen, A., Gerard, R., Xia, F., Schinzel, R.T., Amrein,
K.E., Cowan, C.A., 2015. White-to-brown metabolic conversion of human adipocytes
by JAK inhibition. Nat. Cell Biol. 17:57–67. http://dx.doi.org/10.1038/ncb3075.
Munoz, D.M., Cassiani, P.J., Li, L., Billy, E., Korn, J.M., Jones, M.D., Golji, J., Ruddy, D.A., Yu, K.,
McAllister, G., DeWeck, A., Abramowski, D., Wan, J., Shirley, M.D., Neshat, S.Y., Rakiec,
D., de Beaumont, R., Weber, O., Kauffmann, A., McDonald, E.R., Keen, N., Hofmann, F.,
Sellers, W.R., Schmelzle, T., Stegmeier, F., Schlabach, M.R., 2016. CRISPR screens pro-
vide a comprehensive assessment of cancer vulnerabilities but generate false-positive
hits for highly amplified genomic regions. Cancer Discov. 6:900–913. http://dx.doi.
org/10.1158/2159-8290.CD-16-0178.
Neumann, B., Held, M., Liebel, U., Erfle, H., Rogers, P., Pepperkok, R., Ellenberg, J., 2006.
High-throughput RNAi screening by time-lapse imaging of live human cells. Nat.
Methods 3:385–390. http://dx.doi.org/10.1038/nmeth876.
Pastrana, E., Silva-Vargas, V., Doetsch, F., 2011. Eyes wide open: a critical review of
sphere-formation as an assay for stem cells. Stem Cells 8:486–498. http://dx.doi.
org/10.1016/j.stem.2011.04.007.
Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R.,
Schacht, A.L., 2010. How to improve R&D productivity: the pharmaceutical industry's
grand challenge. Nat. Rev. Drug Discov.:1–12 http://dx.doi.org/10.1038/nrd3078.
Perlman, Z.E., Slack, M.D., Feng, Y., Mitchison, T.J., Wu, L.F., Altschuler, S.J., 2004. Multidi-
mensional drug profiling by automated microscopy. Science 306:1194–1198. http://
dx.doi.org/10.1126/science.1100709.
Pierce, G.B., Speers, W.C., 1988. Tumors as caricatures of the process of tissue renewal:
prospects for therapy by directing differentiation. Cancer Res. 48, 1996–2004.
Pilz, G.-A., Shitamukai, A., Reillo, I., Pacary, E., Schwausch, J., Stahl, R., Ninkovic, J., Snippert,
H.J., Clevers, H., Godinho, L., Guillemot, F., Borrell, V., Matsuzaki, F., Götz, M., 2013.
Amplification of progenitors in the mammalian telencephalon includes a new radial
glial cell type. Nat. Commun. 4. http://dx.doi.org/10.1038/ncomms3125.
Pollard, S.M., Yoshikawa, K., Clarke, I.D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head,
R., Lee, M., Bernstein, M., Squire, J.A., Smith, A., Dirks, P., 2009. Glioma stem cell lines
expanded in adherent culture have tumor-specific phenotypes and are suitable for
chemical and genetic screens. Cell Stem Cell 4:568–580. http://dx.doi.org/10.1016/j.
stem.2009.03.014.
Pourquié, O., Bruneau, B., Keller, G., Smith, A., 2015. Looking inwards: opening a window
onto human development. Development 142:1–2. http://dx.doi.org/10.1242/dev.
119727.
Reaume, A.G., 2012. Drug repurposing through nonhypothesis driven phenotypic screen-
ing. Drug Discov. Today 8:85–88. http://dx.doi.org/10.1016/j.ddstr.2011.09.007.
Rowitch, D.H., Kriegstein, A.R., 2010. Developmental genetics of vertebrate glial-cell spec-
ification. Nature 468:214–222. http://dx.doi.org/10.1038/nature09611.
Sanai, N., Tramontin, A.D., Quinones-Hinojosa, A., Barbaro, N.M., Gupta, N., Kunwar, S.,
Lawton, M.T., McDermott, M.W., Parsa, A.T., Verdugo, J.M.-G., Berger, M.S., Alvarez-
Buylla, A., 2004. Unique astrocyte ribbon in adult human brain contains neural
stem cells but lacks chain migration. Nature 427:740–744. http://dx.doi.org/10.
1038/nature02301.
Sancho-Martinez, I., Nivet, E., Xia, Y., Hishida, T., Aguirre, A., Ocampo, A., Ma, L., Morey, R.,
Krause, M.N., Zembrzycki, A., Ansorge, O., Vazquez-Ferrer, E., Dubova, I., Reddy, P.,
Lam, D., Hishida, Y., Wu, M.-Z., Esteban, C.R., O'Leary, D., Wahl, G.M., Verma, I.M.,
Laurent, L.C., Izpisúa Belmonte, J.C., 2016. Establishment of human iPSC-basedmodels
for the study and targeting of glioma initiating cells. Nat. Commun. 7:10743. http://
dx.doi.org/10.1038/ncomms10743.
Scannell, J.W., Blanckley, A., Boldon, H., Warrington, B., 2012. Diagnosing the decline in
pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11:1–10. http://dx.doi.org/10.
1038/nrd3681.
Shalem, O., Sanjana, N.E., Hartenian, E., Shi, X., Scott, D.A., Mikkelsen, T.S., Heckl, D., Ebert, B.L.,
Root, D.E., Doench, J.G., Zhang, F., 2014. Genome-scale CRISPR-Cas9 knockout screening
in human cells. Science 343:84–87. http://dx.doi.org/10.1126/science.1247005.
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J., Dirks, P.B., 2003.
Identification of a cancer stem cell in human brain tumors. Cancer Res. 63,
5821–5828.g discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
10 E. O'Duibhir et al. / Molecular and Cellular Neuroscience xxx (2016) xxx–xxxSingh, S.K., Singh, S.K., Hawkins, C., Hawkins, C., Clarke, I.D., Clarke, I.D., Squire, J.A., Squire,
J.A., Bayani, J., Bayani, J., Hide, T., Hide, T., Henkelman, R.M., Henkelman, R.M.,
Cusimano, M.D., Cusimano, M.D., Dirks, P.B., Dirks, P.B., 2004. Identification of
human brain tumour initiating cells. Nature 432:396–401. http://dx.doi.org/10.
1038/nature03128.
Smith, K., Horvath, P., 2014. Active learning strategies for phenotypic profiling of high-
content screens. J. Biomol. Screen. 19:685–695. http://dx.doi.org/10.1177/
1087057114527313.
Staunton, J.E., Slonim, D.K., Coller, H.A., Tamayo, P., Angelo, M.J., Park, J., Scherf, U., Lee, J.K.,
Reinhold, W.O., Weinstein, J.N., Mesirov, J.P., Lander, E.S., Golub, T.R., 2001.
Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. U. S.
A. 98:10787–10792. http://dx.doi.org/10.1073/pnas.191368598.
Stiles, C.D., Stiles, C.D., Rowitch, D.H., Rowitch, D.H., 2008. Glioma stem cells: a midterm
exam. Neuron 58:832–846. http://dx.doi.org/10.1016/j.neuron.2008.05.031.
Stransky, N., Ghandi, M., Kryukov, G.V., Garraway, L.A., Lehár, J., Liu, M., Sonkin, D.,
Kauffmann, A., Venkatesan, K., Edelman, E.J., Riester, M., Barretina, J., Caponigro, G.,
Schlegel, R., Sellers, W.R., Stegmeier, F., Morrissey, M., Amzallag, A., Pruteanu-
Malinici, I., Haber, D.A., Ramaswamy, S., Benes, C.H., Menden, M.P., Iorio, F., Stratton,
M.R., McDermott, U., Garnett, M.J., Saez-Rodriguez, J., 2015. Pharmacogenomic agree-
ment between two cancer cell line data sets. Nature:1–15 http://dx.doi.org/10.1038/
nature15736.
Sturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D.T.W., Konermann, C.,
Pfaff, E., Tönjes, M., Sill, M., Bender, S., Kool, M., Zapatka, M., Becker, N., Zucknick,
M., Hielscher, T., Liu, X.-Y., Fontebasso, A.M., Ryzhova, M., Albrecht, S., Jacob, K.,
Wolter, M., Ebinger, M., Schuhmann, M.U., Van Meter, T., Frühwald, M.C., Hauch, H.,
Pekrun, A., Radlwimmer, B., Niehues, T., von Komorowski, G., Dürken, M., Kulozik,
A.E., Madden, J., Donson, A., Foreman, N.K., Drissi, R., Fouladi, M., Scheurlen, W., von
Deimling, A., Monoranu, C., Roggendorf, W., Herold-Mende, C., Unterberg, A.,
Kramm, C.M., Felsberg, J., Hartmann, C., Wiestler, B., Wick, W., Milde, T., Witt, O.,
Lindroth, A.M., Schwartzentruber, J., Faury, D., Fleming, A., Zakrzewska, M., Liberski,
P.P., Zakrzewski, K., Hauser, P., Garami, M., Klekner, A., Bognar, L., Morrissy, S.,
Cavalli, F., Taylor, M.D., van Sluis, P., Koster, J., Versteeg, R., Volckmann, R.,
Mikkelsen, T., Aldape, K., Reifenberger, G., Collins, V.P., Majewski, J., Korshunov, A.,
Lichter, P., Plass, C., Jabado, N., Pfister, S.M., 2012. Hotspot mutations in H3F3A and
IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer
Cell 22:425–437. http://dx.doi.org/10.1016/j.ccr.2012.08.024.
Sunkin, S.M., Ng, L., Lau, C., Dolbeare, T., Gilbert, T.L., Thompson, C.L., Hawrylycz, M., Dang,
C., 2013. Allen brain atlas: an integrated spatio-temporal portal for exploring the cen-
tral nervous system. Nucleic Acids Res. 41:D996–D1008. http://dx.doi.org/10.1093/
nar/gks1042.
Tanaka, M., Bateman, R., Rauh, D., Vaisberg, E., Ramachandani, S., Zhang, C., Hansen, K.C.,
Burlingame, A.L., Trautman, J.K., Shokat, K.M., Adams, C.L., 2005a. An unbiased cell
morphology–based screen for new, biologically active small molecules. PLoS Biol. 3,
e128–13. http://dx.doi.org/10.1371/journal.pbio.0030128.
Tanaka, M., Bateman, R., Rauh, D., Vaisberg, E., Ramachandani, S., Zhang, C., Hansen, K.C.,
Burlingame, A.L., Trautman, J.K., Shokat, K.M., Adams, C.L., 2005b. An unbiased cell
morphology–based screen for new, biologically active small molecules. PLoS Biol. 3,
e128–13. http://dx.doi.org/10.1371/journal.pbio.0030128.
Tanikawa, T., Fridman, M., Zhu,W., Faulk, B., Joseph, I.C., Kahne, D., Wagner, B.K., Clemons,
P.A., 2009. Using biological performance similarity to inform disaccharide library de-
sign. J. Am. Chem. Soc. 131:5075–5083. http://dx.doi.org/10.1021/ja806583y.Please cite this article as: O'Duibhir, E., et al., Accelerating glioblastoma dru
and phenotypic screening, Mol. Cell. Neurosci. (2016), http://dx.doi.org/1Taverna, E., Götz, M., Huttner, W.B., 2014. The cell biology of neurogenesis: toward an un-
derstanding of the development and evolution of the neocortex. Annu. Rev. Cell Dev.
Biol. 30:465–502. http://dx.doi.org/10.1146/annurev-cellbio-101011-155801.
Taylor, D.L., Woo, E.S., Giuliano, K.A., 2001. Real-time molecular and cellular analysis: the
new frontier of drug discovery. Curr. Opin. Biotechnol. 12, 75–81.
Toledo, C.M., Ding, Y., Hoellerbauer, P., Davis, R.J., Basom, R., Girard, E.J., Lee, E., Corrin, P.,
Hart, T., Bolouri, H., Davison, J., Zhang, Q., Hardcastle, J., Aronow, B.J., Plaisier, C.L.,
Baliga, N.S., Moffat, J., Lin, Q., Li, X.-N., Nam, D.-H., Lee, J., Pollard, S.M., Zhu, J., Delrow,
J.J., Clurman, B.E., Olson, J.M., Paddison, P.J., 2015. Genome-wide CRISPR-Cas9 screens
reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like
cells. Cell Rep. 13:2425–2439. http://dx.doi.org/10.1016/j.celrep.2015.11.021.
Verginelli, F., Perin, A., Dali, R., Fung, K.H., Lo, R., Longatti, P., Guiot, M.-C., Del Maestro, R.F.,
Rossi, S., di Porzio, U., Stechishin, O., Weiss, S., Stifani, S., 2013. Transcription factors
FOXG1 and Groucho/TLE promote glioblastoma growth. Nat. Commun. 4:1–16.
http://dx.doi.org/10.1038/ncomms3956.
Wagner, B.K., Clemons, P.A., 2009. Connecting synthetic chemistry decisions to cell and
genome biology using small-molecule phenotypic profiling. Curr. Opin. Chem. Biol.
13:539–548. http://dx.doi.org/10.1016/j.cbpa.2009.09.018.
Wawer, M.J., Li, K., Gustafsdottir, S.M., Ljosa, V., Bodycombe, N.E., Marton, M.A., Sokolnicki,
K.L., Bray, M.-A., Kemp, M.M., Winchester, E., Taylor, B., Grant, G.B., Hon, C.S.-Y.,
Duvall, J.R., Wilson, J.A., Bittker, J.A., Dančík, V., Narayan, R., Subramanian, A.,
Winckler, W., Golub, T.R., Carpenter, A.E., Shamji, A.F., Schreiber, S.L., Clemons, P.A.,
2014. Toward performance-diverse small-molecule libraries for cell-based phenotyp-
ic screening using multiplexed high-dimensional profiling. PNAS 111:10911–10916.
http://dx.doi.org/10.1073/pnas.1410933111.
Wenzel, C., Riefke, B., Gründemann, S., Krebs, A., Christian, S., Prinz, F., Osterland, M.,
Golfier, S., Räse, S., Ansari, N., Esner, M., Bickle, M., Pampaloni, F., Mattheyer, C.,
Stelzer, E.H., Parczyk, K., Prechtl, S., Steigemann, P., 2014. 3D high-content screening
for the identification of compounds that target cells in dormant tumor spheroid re-
gions. Exp. Cell Res. 323:131–143. http://dx.doi.org/10.1016/j.yexcr.2014.01.017.
Wurdak, H., Zhu, S., Romero, A., Lorger, M., Watson, J., Chiang, C.Y., Zhang, J., Natu, V.S.,
Lairson, L.L., Walker, J.R., Trussell, C.M., Harsh, G.R., Vogel, H., Felding-Habermann,
B., Orth, A.P., Miraglia, L.J., Rines, D.R., Skirboll, S.L., Schultz, P.G., 2010. An RNAi screen
identifies TRRAP as a regulator of brain tumor-initiating cell differentiation. Cell Stem
Cell 6:37–47. http://dx.doi.org/10.1016/j.stem.2009.11.002.
Xie, Y., Bergström, T., Jiang, Y., Johansson, P., Marinescu, V.D., Lindberg, N., Segerman, A.,
Wicher, G., Niklasson, M., Baskaran, S., Sreedharan, S., Everlien, I., Kastemar, M.,
Hermansson, A., Elfineh, L., Libard, S., Holland, E.C., Hesselager, G., Alafuzoff, I.,
Westermark, B., Nelander, S., Forsberg-Nilsson, K., Uhrbom, L., 2015. The human glio-
blastoma cell culture resource: validated cell models representing all molecular sub-
types. EBioMedicine 2:1351–1363. http://dx.doi.org/10.1016/j.ebiom.2015.08.026.
Yarrow, J.C., Feng, Y., Perlman, Z.E., Kirchhausen, T., Mitchison, T.J., 2003. Phenotypic
screening of small molecule libraries by high throughput cell imaging. Comb. Chem.
High Throughput Screen. 6, 279–286.
Young, D.W., Bender, A., Hoyt, J., McWhinnie, E., Chirn, G.-W., Tao, C.Y., Tallarico, J.A.,
Labow,M., Jenkins, J.L., Mitchison, T.J., Feng, Y., 2007. Integrating high-content screen-
ing and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4:
59–68. http://dx.doi.org/10.1038/nchembio.2007.53.g discovery: Convergence of patient-derived models, genome editing
0.1016/j.mcn.2016.11.001
